Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer.

Vuky J; Balar AV; Castellano D; O'Donnell PH; Grivas P; Bellmunt J; Powles T; Bajorin D; Hahn NM; Savage MJ

doi:10.1200/jco.19.01213

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer.

Identifier:nobleid.org/w1/20260526/3DBB86E1

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/3DBB86E1.svg?ark=w1%2F20260526%2F3DBB86E1)](https://nobleid.org/work/w1/20260526/3DBB86E1)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer.

Identifier:nobleid.org/w1/20260526/3DBB86E1

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/3DBB86E1.svg?ark=w1%2F20260526%2F3DBB86E1)](https://nobleid.org/work/w1/20260526/3DBB86E1)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work